Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Intracerebral Haemorrhage
Phase PHASE4
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \<140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Combination Product: Nicardipine — Nicardipine infusion based acute blood pressure lowering treatment
  • Combination Product: Glyceryl trinitrate — Glyceryltrinitrate based acute blood pressure lowering treatment

Primary Outcomes

  • Target blood pressure < 140 mmHg 1 hour after admission. (1 hour after stroke center admission)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aarhus University Hospital
Contact Information
Study Contact:
Rolf Blauenfeldt, MD, PhD
+4520774053
rolfblau@rm.dk
Claus Z Simonsen, MD, PhD
clausimo@rm.dk
Rolf Blauenfeldt
+4529318244
rolfblau@rm.dk
Aarhus University Hospital
Interventions
  • Combination Product: Nicardipine — Nicardipine infusion based acute blood pressure lowering treatment
  • Combination Product: Glyceryl trinitrate — Glyceryltrinitrate based acute blood pressure lowering treatment
Study Locations (1 sites)
Aarhus University Hospital, Aarhus, 8200 Denmark
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Acute spontaneous Intracerberal Hemorrhage confirmed by imaging * Symptom onset to stroke center admission \<6 hours * Elevated systolic blood pressure (\>140 mmHg) at admission Exclusion Criteria: * Secondary causes of ICH (e.g., trauma, vascular malformation) * Presumed fatal bleeding at admission * Short remaining life expectancy (\<12 month)

Symplicity China Study

NCT07081243
Recruiting
Conditions Resistant Hypertension
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of follow up.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Symplicity Spyral Renal Denervation System — Symplicity Renal Denervation

Primary Outcomes

  • Primary Objective: Change in systolic blood pressure (SBP) from baseline to 6 months post-procedure as measured by office blood pressure. (6 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-11
Completion: 2031-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medtronic Vascular
Contact Information
Study Contact:
Zhifeng Yao
0086-21-64041990
zhifengyao@126.com
Zhongshan Hospital Fudan University
Interventions
  • Device: Symplicity Spyral Renal Denervation System — Symplicity Renal Denervation
Study Locations (1 sites)
Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality 210000 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18 years or older. 2. Patients diagnosed with resistant hypertension or antihypertensive drug intolerance and treated with Symplicity Spyral Renal Denervation System. Resistant hypertension, defined as having an office systolic blood pressure (SBP) ≥140 mmHg despite appropriate lifestyle measures and being treated with three or more antihypertensive medications (including a diuretic) for more than 3 months; or drug intolerance, defined as patients who cannot tolerate medication due to contraindications or adverse effects. 3. The patient voluntarily undergoes renal denervation; the patient has been informed of the observational nature of the study; the patient voluntarily provides written informed consent ("Patient Informed Consent Form") and willingly participates in the study. Exclusion Criteria: 1. At least one main renal artery with a diameter less than 3 mm or greater than 8 mm. 2. Presence of fibromuscular dysplasia. 3. Renal artery stent placement within 3 months prior to the procedure. 4. Presence of Renal artery aneurysms. 5. Presence of more than 50% stenosis in any treatable vessel. 6. Pregnant. 7. Present of renal or adrenal tumors. 8. Iliac/femoral artery stenosis prevents catheter insertion.
Conditions Type 2 Diabetes, Overweight and Obese Ad...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. Participants will meet with a physician and a registered dietitian once a week to learn about a plant-based diet and receive support and practical help in making the dietary changes. Body composition, blood sugar control, cholesterol levels, and food costs will be measured at the start and end of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Low-fat, vegan diet — All participants will be asked to follow a low-fat vegan diet for the duration of the study. Participants will attend weekly classes where they we receive education and support.

Primary Outcomes

  • The feasibility of an online plant-based weight loss program in the community setting. (From baseline to the end of the intervention at 12 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-02
Completion: 2028-10-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Physicians Committee for Responsible Medicine
Contact Information
Study Contact:
Vanita Rahman, MD, DipACLM
202-527-7500
vrahman@pcrm.org
Shannon Menhardt, MS, RD
202-527-7500
smenhardt@pcrm.org
Vanita Rahman, MD
202-527-7500
vrahman@pcrm.org
Physicians Committee for Responsible Medicine
Interventions
  • Behavioral: Low-fat, vegan diet — All participants will be asked to follow a low-fat vegan diet for the duration of the study. Participants will attend weekly classes where they we receive education and support.
Study Locations (1 sites)
Physicians Committee for Responsible Medicine, Washington D.C., District of Columbia 20016 United States
Eligibility Criteria
Inclusion Criteria: * U.S. men and women meeting the age of majority, defined as follows: Age 19 or older in Nebraska and Alabama. Age 21 or older in Puerto Rico. Age 18 or older in all other states. * Able and willing to travel to Washington DC for a dual-energy х-rау absorptiometry (DXA) scans before and after the program. * Able and willing to complete laboratory assessments at a local LabCorp facility before and after the program. * Able and willing to participate in all components of the study. * BMI of 25 or more (23 or more in persons of Asian origin). * Access to the internet. * English fluency. Exclusion Criteria: * Use of recreational drugs in the past 6 months. * Pregnancy or intention to become pregnant during the study period, as verified by self-report. * Unstable medical or psychiatric illness. * Inability to maintain medication regimen as prescribed by personal healthcare provider. * Current or expected use of any weight loss medication during the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor/glucose-dependent insulinotropic polypeptide (GIP) agonists. * Use of any weight loss medication within the 12 months preceding the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor/glucose-dependent insulinotropic polypeptide (GIP) agonists. * Body weight greater than 182 kg. * Current diagnosis of eating disorder. * Intention to follow another weight loss method during the study period.
Conditions Breast Cancer
Phase PHASE2
Enrollment 768
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Ultrahypofractionated Radiation — Given by infusion
  • Radiation: Moderately Hypofractionated Radiation — Given by infusion

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-19
Completion: 2031-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 768 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Benjamin Smith, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Benjamin Smith, MD
(713) 563-2380
bsmith3@mdanderson.org
Supriya Jain, MD
supriya.jain@bannerhealth.com
Banner MD Anderson Northern Colorado
Supriya Jain, MD
Banner MD Anderson Northern Colorado
Interventions
  • Radiation: Ultrahypofractionated Radiation — Given by infusion
  • Radiation: Moderately Hypofractionated Radiation — Given by infusion
Study Locations (5 sites)
Banner MD Anderson Northern Colorado, Loveland, Colorado 80538 United States
Baptist MD Anderson, Jacksonville, Florida 32207 United States
Cooper Hospital University Medical Center, Voorhees Township, New Jersey 08103 United States
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: Eligibility Criteria Applicable to All Cohorts Histologically confirmed invasive breast cancer (nodal involvement from presumed invasive breast cancer in the setting of occult breast cancer is sufficient to meet this criteria) 1\. Regional nodal irradiation recommended by treating radiation oncologist. 2 Negative final surgical margins. 3 No more than 12 weeks have elapsed since final breast/lymph node surgery for patients treated with surgery alone or neoadjuvant chemotherapy. No more than 12 weeks have elapsed since final cytotoxic chemotherapy for patients who received adjuvant chemotherapy. 5. Age ≥18 years. Because breast cancer is exceedingly rare in patients \< 18 years of age, children are excluded from this study. 6. Patients with a prior or concurrent malignancy are eligible provided that the natural history and treatment of the prior or concurrent malignancy does not interfere with the safety or efficacy assessment of the investigational radiation regimen used in this trial. 7. Ability to understand and the willingness to sign a written informed consent document. 8. Concurrent enrollment on other observational, translational, or therapeutic studies is allowed provided there is no direct conflict between the other protocol and the radiation regimen proscribed in this trial. Eligibility Criteria for the Low-Risk Lumpectomy Cohort 1. For patients treated with upfront surgery, pathologic stage pT0-T4b N0-N3a breast cancer without infraclavicular or internal mammary nodal involvement. 2. For patients treated with neoadjuvant chemotherapy, clinical stage cT0-T4b N0-N2a breast cancer. 3. Treated with lumpectomy (or axillary surgery only in the case of occult primary breast cancer) 4. No nodal boost recommended by the treating radiation oncologist. Eligibility Criteria for the High-Risk Lumpectomy Cohort 1. Treated with neoadjuvant chemotherapy 2. Clinical stage cT0-T4b N1-N3a/b/c 3. Treated with lumpectomy (or axillary surgery only in the case of occult primary breast cancer) 4. Nodal boost recommended by the treating radiation oncologist. Eligibility Criteria for the Low-Risk Mastectomy Cohort 1. For patients treated with upfront surgery, pathologic stage T0-T2 N0-N2a 2. For patients treated with neoadjuvant chemotherapy, clinical stage T0-T3 N0- N2a 3. For patients treated with neoadjuvant chemotherapy, residual cellularity of primary tumor ≤ 20%. 4. Treated with mastectomy 5. Negative surgical margins ≥ 2 mm. 6. No or only focal lymphovascular space invasion. 7. Age ≥ 40 years 8. Chest wall boost NOT recommended by treating radiation oncologist. Eligibility Criteria for High-Risk Mastectomy Cohort 1. For patients treated with upfront surgery, pathologic stage T0-T4d N0-N3c 2. For patients treated with neoadjuvant chemotherapy, clinical stage T0-T4d N0- N3c 3. Treated with mastectomy 4. Chest wall boost and/or nodal boost recommended by treating radiation oncologist Pregnancy Status (applicable to all cohorts) Therapeutic radiation is known to be teratogenic. As a result, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of radiation treatment. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the radiation therapy course is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception during the radiation treatment course. Pregnancy testing at the time of study enrollment is not required of women who enroll. However, all patients must comply with the Institutional Pregnancy Assessment Policy (# CLN1114) which requires pregnancy testing within 7 days prior to simulation. Exclusion Criteria: History of therapeutic radiation overlapping with the index breast or nodal basins that require radiation therapy. History of scleroderma Pregnant women are excluded from this study because ionizing radiation has the potential for teratogenic or abortifacient effects. Patients with psychiatric illness/social situations that would limit compliance with study requirements
Conditions Diabetic Peripheral Neuropathy, Diabetic...
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Melatonin — Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway. Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice.

Primary Outcomes

  • Concentration of human nuclear factor erythroid 2-related factor (Nrf2) (Change from baseline human Nuclear factor erythroid 2-related factor at 3 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-04
Completion: 2027-07-04
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Contact Information
Study Contact:
Manar Magdy Demonstrator at ain shams university
01113177801
manar.magdy17@pharma.asu.edu.eg
Ain Shams University hospital
Interventions
  • Drug: Melatonin — Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway. Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice.
Study Locations (1 sites)
Ain Shams University hospital, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 40-75 years diagnosed with type 2 DM. 2. Diabetes duration at least 1 year. 3. Patients diagnosed with diabetic peripheral neuropathy. 4. Stable antidiabetic medication for at least 1 month before enrollment and during the trial Exclusion Criteria: 1. Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients. 2. Patients with severe kidney or liver dysfunction. 3. Patients diagnosed with neurodegenerative diseases. 4. Active infection. 5. Use of medications or supplements known to cause or treat peripheral neuropathy. 6. Alcohol consumption or substance abuse. 7. Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment. 8. Pregnancy or lactation or expecting to get pregnant during the study. 9. Allergy to melatonin.
Conditions Diabetes Type 2, Insomnia
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Insomnia is highly prevalent in individuals with type 2 diabetes (T2D) and is associated with poor glycemic control. Louisiana has one of the highest diabetes prevalence rates in the U.S., with significant disparities by race, income, and rural residence. Despite growing recognition of sleep's role in diabetes management, sleep disturbances remain largely unaddressed in diabetes care. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia, yet it is underutilized in primary care clinics such as federally qualified health centers (FQHCs) that serve high-risk populations. The long-term goal of this research is to improve cardiometabolic health and reduce diabetes disparities by integrating sleep interventions into diabetes care. This pilot study aims to: (1) evaluate the impact of CBT-I on sleep and diabetes-related outcomes, and (2) assess the acceptability, feasibility, and fidelity of implementing a 6-week CBT-I program in an FQHC setting. The investigators will conduct a randomized controlled trial (RCT) with 30 FQHC patients (aged 40+) with uncontrolled T2D (HbA1c \>7%) and comorbid insomnia (Insomnia Severity Index (ISI) score ≥15). Participants will be randomly assigned to either the CBT-I intervention or usual care. Sleep (ISI scores, actigraphy) and cardiometabolic (HbA1c, fasting glucose, insulin) outcomes will be assessed at baseline and three months post-randomization. Implementation success will be evaluated using fidelity, feasibility, and acceptability measures. Findings will provide preliminary evidence for integrating CBT-I into primary care, informing larger trials to improve diabetes outcomes and reduce disparities in Louisiana.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy for Insomnia — 6 weekly sessions delivered by a Sleep Coaching Team comprised of a federally qualified health center behavioral health provider and a health coach, focusing on stimulus control, sleep restriction, and cognitive therapy
  • Other: Usual care for diabetes management — Usual clinical care for management of diabetes (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
  • Other: Usual care for treatment of insomnia — Usual clinical care for treatment of insomnia (may include pharmacological and non-pharmacological approaches as determined by provider and patient)

Primary Outcomes

  • Between-group difference in change in HbA1c from baseline to 3 months (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2027-06-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tulane University
Contact Information
Study Contact:
Erin Peacock, PhD, MPH
504-988-1075
epeacoc@tulane.edu
Erin Peacock, PhD, MPH
504-988-1075
epeacoc@tulane.edu
Southeast Community Health Systems
Interventions
  • Behavioral: Cognitive Behavioral Therapy for Insomnia — 6 weekly sessions delivered by a Sleep Coaching Team comprised of a federally qualified health center behavioral health provider and a health coach, focusing on stimulus control, sleep restriction, and cognitive therapy
  • Other: Usual care for diabetes management — Usual clinical care for management of diabetes (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
  • Other: Usual care for treatment of insomnia — Usual clinical care for treatment of insomnia (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
Study Locations (1 sites)
Southeast Community Health Systems, Zachary, Louisiana 70791 United States
Eligibility Criteria
Inclusion Criteria: * aged 40 or older * receive primary care from participating clinic * diagnosis of type 2 diabetes * most recent hemoglobin A1c (HbA1c) \>7% within the past year * Insomnia Severity Index (ISI) score ≥15 * able to speak English Exclusion Criteria: * diagnosed or self-reported sleep apnea * pregnant or planning to become pregnant during the study period * having a psychiatric or medical condition that would interfere with the ability to complete study procedures * participating in another diabetes clinical trial * living in same household as another participant * required to work night shifts
Conditions Hypertension, Fall Risk, Postural Balanc...
Phase NA
Enrollment 186
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the short-term effects of three commonly prescribed antihypertensive drug classes (beta-blockers, ACE inhibitors, and calcium channel blockers) on postural balance and fall risk in adults with newly diagnosed primary hypertension. The main questions it aims to answer are: * Do different antihypertensive drugs affect objective balance performance and fall risk? * What are the effects of these medications on dizziness and fear of falling? Researchers will use a balance analysis system (Biodex Balance System) and self-reported scales (Dizziness Handicap Inventory and Falls Efficacy Scale) to assess outcomes. Participants will: * Be randomly assigned to one of three drug groups (metoprolol, ramipril, or amlodipine) * Be evaluated at baseline (prior to treatment), at 2 weeks, and at 4 weeks after starting treatment * Complete balance tests and questionnaires at each time point This study aims to provide clinical insight into how commonly used blood pressure medications may impact balance and fall risk in real-world settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Beta Blocker — Participants in this group will receive standard antihypertensive treatment with a beta-adrenergic receptor blocker. The exact agent and dosage will be determined by the cardiology clinic according to clinical guidelines. Balance and fall risk assessments will be conducted at baseline (T0), week 2 (T1), and week 4 (T2).
  • Drug: ACE inhibitor — Participants in this group will receive standard antihypertensive treatment with an angiotensin-converting enzyme inhibitor. The dose and specific agent will be prescribed based on routine clinical criteria. Assessments will take place at T0, T1, and T2.
  • Drug: Calcium channel blocker — This group will receive a calcium channel blocker as part of their standard hypertension management. Dosage and agent will follow standard cardiology practice. Postural balance and fall risk will be measured at all study time points.

Primary Outcomes

  • Fall Risk Score (Biodex Balance System) (Baseline (T0), Week 2 (T1), Week 4 (T2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-01
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 186 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abant Izzet Baysal University
Principal Investigators:
  • Alp Ozel, PT, PhD (PRINCIPAL_INVESTIGATOR) - Abant Izzet Baysal University
Contact Information
Study Contact:
Alp Ozel, PT, PhD
+903742534520
alpozel@ibu.edu.tr
Umut A Ugras, MD
+905066434435
umutataugras@gmail.com
Interventions
  • Drug: Beta Blocker — Participants in this group will receive standard antihypertensive treatment with a beta-adrenergic receptor blocker. The exact agent and dosage will be determined by the cardiology clinic according to clinical guidelines. Balance and fall risk assessments will be conducted at baseline (T0), week 2 (T1), and week 4 (T2).
  • Drug: ACE inhibitor — Participants in this group will receive standard antihypertensive treatment with an angiotensin-converting enzyme inhibitor. The dose and specific agent will be prescribed based on routine clinical criteria. Assessments will take place at T0, T1, and T2.
  • Drug: Calcium channel blocker — This group will receive a calcium channel blocker as part of their standard hypertension management. Dosage and agent will follow standard cardiology practice. Postural balance and fall risk will be measured at all study time points.
Study Locations (1 sites)
Bolu Abant Izzet Baysal University, Izzet Baysal Training and Research Hospital, Bolu, 14030 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 75 years * Newly diagnosed with primary hypertension * No prior use of antihypertensive medication * No history of neurological, vestibular, orthopedic, or psychiatric conditions affecting balance * Able to walk independently without assistive devices * Provided written informed consent to participate in the study Exclusion Criteria: * Secondary hypertension * Known diagnosis of vestibular disorders (e.g., BPPV, Ménière's disease) * Use of medications that may affect balance (e.g., sedatives, psychotropic drugs) * History of falls due to trauma unrelated to balance * Cognitive impairment preventing proper test participation * Inability to complete the assessments at follow-up timepoints (2nd and 4th week)
Conditions Primary Aldosteronism, Hypertension
Phase Not Applicable
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is: 1. What is the long-term effect of spironolactone treatment for lateralized PA? 2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: spironolactone — The patients receive spironolactone treatment based on their conditions

Primary Outcomes

  • Change of systolic blood pressure (From enrollment to spironolactone treatment at 12 months.)
  • Change of diastolic blood pressure (From enrollment to spironolactone treatment at 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-01
Completion: 2026-04-30
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Third Military Medical University
Principal Investigators:
  • Zhiming Zhu, MD (STUDY_CHAIR) - Department of Hypertension and Endocrinology, Daping Hospital, Army Medical University
Contact Information
Study Contact:
Zhencheng Yan, MD
+8613983656682
zhenchengyan@sina.com
Zhiming Zhu, MD
+8613608313322
hbpcms@sina.com
Daping Hospital, Army Medical Center of PLA
Interventions
  • Drug: spironolactone — The patients receive spironolactone treatment based on their conditions
Study Locations (1 sites)
Daping Hospital, Army Medical Center of PLA, Chongqing, Chongqing Municipality 400042 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female, aged 30\~65 years. 2. PA patients with positive screening tests and saline suppression tests, and with AVS to determine lateralization. These patients have hypertension defined as office blood pressure ≥ 140/90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130/80 mmHg, daytime blood pressure ≥ 135/85 mmHg, or nighttime blood pressure ≥ 120/70 mmHg. 3. Patients with unilateral aldosterone-producing adenoma who decline surgery, or patients with non-adenoma, unilateral PA confirmed by AVS and meeting the above PA-related hypertension criteria. 4. Provision of written informed consent to participate in the study. Exclusion Criteria: 1. Hyperkalemia. 2. Renal impairment or have history of renal disease: serum creatinine \> 1.5 × upper limit of normal (ULN), dialysis, or nephrotic syndrome. 3. Other confirmed secondary hypertension: pheochromocytoma, Cushing's syndrome, thyroid disorders, parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence, etc. 4. Adrenal insufficiency. 5. Heart failure with NYHA class II-IV or stroke. 6. Acute infection, malignancy, severe arrhythmia, psychiatric disorders, or drug/alcohol abuse. 7. Significant hepatic dysfunction or have history of liver disease: AST or ALT \> 2 × ULN, cirrhosis, hepatic encephalopathy, esophageal varices or portosystemic shunt. 8. Pregnancy or lactation. 9. Participation in another clinical trial within the past 3 months. 10. Inability to complete follow-up. 11. Refusal to provide informed consent.
Conditions Metastatic Breast Cancer, Drug Resistanc...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a real-world observational study aiming to evaluate the effectiveness of post-progression treatment strategies in patients with advanced breast cancer who have developed resistance to prior targeted therapies, including CDK4/6 inhibitors, PIK3CA inhibitors, trastuzumab deruxtecan (T-DXd), or other targeted agents commonly used in clinical practice. As resistance to these therapies becomes increasingly common, optimal sequencing strategies for subsequent treatment remain unclear. This study will collect clinical information on post-resistance systemic treatments and their outcomes, including progression-free survival, overall survival, and response rate. Baseline patient and tumor characteristics will also be collected to explore potential prognostic and predictive factors and to develop outcome prediction models that may help guide future clinical decision-making. This is a non-interventional study based on retrospective and prospective data from routine medical care. The results are expected to provide real-world evidence to inform personalized treatment strategies for patients with advanced breast cancer following resistance to targeted therapies.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Progression-Free Survival (PFS) (From the start of post-resistance systemic treatment until documented disease progression or death, up to 36 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2026-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Binliang Liu, M.D
+8617370789834
liubinliang_onco@163.com
Binliang Liu
073189762161
liubinliang_onco@163.com
Hunan Cancer Hospital
Interventions
N/A
Study Locations (1 sites)
Hunan Cancer Hospital, Changsha, Hunan 410013 China
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥18 years old) with histologically or cytologically confirmed advanced or metastatic breast cancer 2. Received prior treatment with at least one of the following: CDK4/6 inhibitors, PIK3CA inhibitors, trastuzumab deruxtecan (T-DXd), or other targeted therapies 3. Documented disease progression following prior targeted therapy 4. Initiated a subsequent line of systemic therapy (chemotherapy, endocrine therapy, targeted therapy, or combination) after resistance 5. Available clinical data including baseline characteristics and treatment details 6. At least one follow-up evaluation after initiation of post-resistance therapy Exclusion Criteria: 1. Incomplete medical records or missing key clinical follow-up data 2. Concurrent diagnosis of other active malignancies (except non-melanoma skin cancer or in situ cervical cancer) 3. Known central nervous system disease requiring immediate local treatment (unless clinically stable) 4. Poor general condition with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2 5. Life expectancy estimated to be less than 6 months based on clinical judgment
Conditions Major Depressive Disorder (MDD), Breast ...
Phase NA
Enrollment 26376
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer among women worldwide, and many survivors experience comorbid mental health conditions such as depression and anxiety, which can significantly worsen health outcomes and increase mortality. This large-scale trial in Pakistan aims to evaluate the clinical and cost-effectiveness of a three-stage adaptive intervention to manage depression among breast cancer survivors. Using a Sequential, Multiple Assignment, Randomised Trial (SMART) design, the study will recruit 26,372 participants aged 18 and above who have completed initial breast cancer treatment (surgery and/or chemotherapy or radiotherapy). Participants will be identified through primary care units, outpatient departments, oncology clinics in public hospitals, and charitable organisations across Pakistan. Depression will be screened using the Patient Health Questionnaire PHQ-9, with diagnosis confirmed by the Structured Clinical Interview Schedule of DSM (SCID). Those randomised to the intervention arm will receive adaptive interventions: starting with low-intensity guided self-help, followed by a high-intensity cognitive behavioural therapy-based programme called "Moving On After Breast Cancer Plus" (Moving on ABC Plus), and for non-responders, an additional pharmacological component will be introduced. Participants in both adaptive intervention and enhance usual care groups will be assessed at multiple time points-baseline, 6, 18, 30, and 48 weeks post-randomisation-using validated tools to measure depression (primary outcome), and anxiety, self-esteem, intrusive thoughts, health-related quality of life, satisfaction with services, and health resource use (secondary outcomes). The study will also include qualitative interviews and focus groups discussions with patients, caregivers, healthcare providers, and policymakers to identify barriers and facilitators to implementation and ensure the intervention is both contextually appropriate and scalable.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Non-specialist delivered Low intensity guided self-help (Khushi and Khatoon) — This is a manualised intervention comprising of 8 chapters. This is being further co-adapted to contexualise this for breast cancer survivours. The original manual is focused on stories of two breast cancer survivors , Mrs Khushi, means happiness) and Khatoon, means woman in Urdu, with depression and anxiety, describing how they help themselves using CBT strategies.
  • Other: Moving on After Breast Cancer (ABC) plus — This is a high intensity manualised intervention consisting of 12 sessions (60-90 minutes). This manual offers practical support and advice on life after breast cancer, managing difficulties, mindfulness, addressing fatigue, understanding the participant's model of illness, improving personal effectiveness and social relationships. The sessions also include therapist delivered psychoeducation using a CBT model of case formulation and goal setting: identification and formulation of predisposing, precipitating, perpetuating and protective factors of depression and/or anxiety, helping participants to identify core beliefs, where necessary, using downward arrow technique, identifying, and challenging unhealthy thinking patterns at the level of core beliefs using cognitive restructuring, and problem-solving techniques
  • Drug: Standardised pharmacological treatment (antidepressants) — Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks. After that, flexible titation of sertraline will be permitted, by 50mg increment every 1 to 2 weeks, as clinically indicated and tolerated to a maximum daily dose of 200 mg
  • Other: Enhanced Treatment As Usual (E-TAU) — Participants in this arm will continue to follow their routine visits to healthcare facilities. They will be regularly monitored by trained research team and will be assessed at weeks 6,18,30, and 48. In addition to psychological assessment at each follow-up, this will include information leaflets based on a brief psychoeducational module to educate participants and families about the risks, symptoms, management, and referral support information for anxiety and depression

Primary Outcomes

  • Hamilton Rating Scale for Depression (Change in total score from baseline to week 48)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-13
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 26376 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pakistan Institute of Living and Learning
Collaborators: University of Sheffield, University of Manchester
Principal Investigators:
  • Nasim Chaudhry, MD (PRINCIPAL_INVESTIGATOR) - Pakistan Institute of Living and Learning
Contact Information
Study Contact:
Tayyeba Kiran, PhD
0923328262142
tayyaba.kiran@pill.org.pk
Nasim Chaudhry, MD
0922135371084
nasim.chaudhry@pill.org.pk
Tayyeba Kiran, PhD
0923328262142
tayyaba.kiran@pill.org.pk
Pakistan Institute of Living and Learning
Interventions
  • Other: Non-specialist delivered Low intensity guided self-help (Khushi and Khatoon) — This is a manualised intervention comprising of 8 chapters. This is being further co-adapted to contexualise this for breast cancer survivours. The original manual is focused on stories of two breast cancer survivors , Mrs Khushi, means happiness) and Khatoon, means woman in Urdu, with depression and anxiety, describing how they help themselves using CBT strategies.
  • Other: Moving on After Breast Cancer (ABC) plus — This is a high intensity manualised intervention consisting of 12 sessions (60-90 minutes). This manual offers practical support and advice on life after breast cancer, managing difficulties, mindfulness, addressing fatigue, understanding the participant's model of illness, improving personal effectiveness and social relationships. The sessions also include therapist delivered psychoeducation using a CBT model of case formulation and goal setting: identification and formulation of predisposing, precipitating, perpetuating and protective factors of depression and/or anxiety, helping participants to identify core beliefs, where necessary, using downward arrow technique, identifying, and challenging unhealthy thinking patterns at the level of core beliefs using cognitive restructuring, and problem-solving techniques
  • Drug: Standardised pharmacological treatment (antidepressants) — Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks. After that, flexible titation of sertraline will be permitted, by 50mg increment every 1 to 2 weeks, as clinically indicated and tolerated to a maximum daily dose of 200 mg
  • Other: Enhanced Treatment As Usual (E-TAU) — Participants in this arm will continue to follow their routine visits to healthcare facilities. They will be regularly monitored by trained research team and will be assessed at weeks 6,18,30, and 48. In addition to psychological assessment at each follow-up, this will include information leaflets based on a brief psychoeducational module to educate participants and families about the risks, symptoms, management, and referral support information for anxiety and depression
Study Locations (1 sites)
Pakistan Institute of Living and Learning, Karachi, Sindh 75600 Pakistan
Eligibility Criteria
Inclusion Criteria: * Women * Aged 18 years and above * Diagnosed with breast cancer (any stage) * Completed initial treatment (i.e., surgery and/or radiotherapy or chemotherapy) for breast cancer (even if they are currently on hormonal therapy post-initial treatment) * Total score of 10 or above on the Patient Health Questionnaire (PHQ-9) * Diagnosis of current Major Depressive Episode (MDE) confirmed using the Structured Clinical Interview for DSM-5 (SCID). Exclusion Criteria: * Lacking capacity to provide informed consent, such as those identified by clinicians as having intellectual disabilities, dementia, or severe medical and/or psychiatric illnesses requiring hospitalisation * Unable to engage in assessments or interventions, including those with stage 4 breast cancer experiencing significant symptoms (e.g., metastatic lesions in the lungs, liver, or bones requiring daily treatment for symptomatic relief, such as the daily use of two or more painkillers), which restrict their capacity to participate * Currently receiving psychological therapy or taking antidepressant medications (e.g., SSRIs, SNRIs, or other prescribed antidepressants)
Conditions Tobacco Cessation, Health Warning Label,...
Phase NA
Enrollment 3400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Tobacco use remains persistently high across South Asia, despite numerous public health efforts, and continues to significantly contribute to the burden of non-communicable diseases (NCDs) such as cardiovascular disease, hypertension, diabetes, and stroke. Community pharmacists-widely accessible and trusted within their communities-are an underutilized resource for delivering public health interventions. Graphic health warnings (GHWs), recommended by the World Health Organization (WHO), have been shown to promote smoking cessation, but are rarely paired with personalized counseling by healthcare providers. This study aims to evaluate both the effectiveness and cost-effectiveness of integrating GHWs with pharmacist-led personalized counseling at primary healthcare pharmacies in Bangladesh and Pakistan. A cluster randomized controlled trial (RCT) will be conducted, enrolling 3,240 adult participants in Bangladesh and \~160 participants in Pakistan (for feasibility study) from community pharmacies. Participants will be randomly assigned to one of three groups: (1) GHW only (distribution of printed booklets); (2) GHW + counseling (pharmacist-led counselling sessions based on booklets at baseline and six months, with monthly SMS reminders); or (3) standard care (usual pharmacy services with no additional materials). The intervention includes twice-yearly counseling sessions-delivered both in-person and digitally-supported by educational booklets and leaflets. The primary outcome is self-reported 7-day point prevalence abstinence at 12 months (validated where feasible). Secondary outcomes include reduction in cigarettes per day, quit attempts, readiness to quit, awareness of tobacco harms, diet and physical activity scores, quality of life, blood pressure control among hypertensive participants, and cost-effectiveness. Feasibility outcomes in Pakistan include recruitment rate, participant retention, intervention fidelity and acceptability. Bayesian statistical models will be used to assess efficacy, and economic evaluations will determine the cost-effectiveness of the interventions. The findings aim to inform scalable public health strategies for tobacco control and NCD prevention in resource-limited settings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Graphical health warnings — This group will receive only graphical health warnings (GHWs) featuring images proposed by the Bangladesh Tobacco Control Cell, explicitly illustrating smoking-related harms, such as mouth diseases, damaged teeth and gums, lung diseases and cancer, heart diseases and cardiovascular damage, and throat and oral cancer. Additionally, these warnings will clearly highlight the benefits of quitting smoking-including improved overall health, reduced disease risks, financial savings, and enhanced quality of life-as well as practical cessation techniques. Participants will receive these GHW materials at baseline and again at the six-month follow-up to reinforce these critical health messages; however, this intervention group will not receive any counselling services. Monthly SMS reminders will also be sent to participants, prompting them to review the GHW leaflet and reinforcing the negative health impacts of smoking and the benefits of quitting.
  • Behavioral: Graphical health warnings plus pharmacist-led counselling — Participants in this group will receive graphical health warnings (GHWs) featuring Bangladesh Tobacco Control Cell-approved images clearly depicting smoking-related harms (e.g., mouth diseases, damaged teeth and gums, lung cancer, heart disease, and oral cancer). Additionally, they will receive personalized counselling from community pharmacists, focused on the specific health and financial benefits of quitting, practical cessation techniques, strategies for overcoming barriers, and relapse prevention. This combined intervention will be provided at baseline and reinforced at a six-month follow-up. Monthly SMS reminders will also be sent, reinforcing key messages on the harmful effects of smoking and benefits of cessation.
  • Other: Routine pharmacy services (no intervention) — Participants in this group will receive only routine pharmacy services based on standard pharmacy practice guidelines applicable in each country. They will not receive any additional graphical health warnings or counselling interventions. Outcomes will be assessed at baseline, 6 months, and 12 months, consistent with the intervention groups.

Primary Outcomes

  • Self-reported 7-day point prevalence abstinence (6 months and 12 months post-intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hitotsubashi University
Collaborators: Global Public Health Research Foundation
Principal Investigators:
  • Md. Mizanur Rahman (PRINCIPAL_INVESTIGATOR) - Hitotsubashi University
Contact Information
Study Contact:
Md. Mizanur Rahman, PhD
+818035463610
mizanurrub78@gmail.com
Kanok Ahammed
Global Public Health Research Foundation
Interventions
  • Behavioral: Graphical health warnings — This group will receive only graphical health warnings (GHWs) featuring images proposed by the Bangladesh Tobacco Control Cell, explicitly illustrating smoking-related harms, such as mouth diseases, damaged teeth and gums, lung diseases and cancer, heart diseases and cardiovascular damage, and throat and oral cancer. Additionally, these warnings will clearly highlight the benefits of quitting smoking-including improved overall health, reduced disease risks, financial savings, and enhanced quality of life-as well as practical cessation techniques. Participants will receive these GHW materials at baseline and again at the six-month follow-up to reinforce these critical health messages; however, this intervention group will not receive any counselling services. Monthly SMS reminders will also be sent to participants, prompting them to review the GHW leaflet and reinforcing the negative health impacts of smoking and the benefits of quitting.
  • Behavioral: Graphical health warnings plus pharmacist-led counselling — Participants in this group will receive graphical health warnings (GHWs) featuring Bangladesh Tobacco Control Cell-approved images clearly depicting smoking-related harms (e.g., mouth diseases, damaged teeth and gums, lung cancer, heart disease, and oral cancer). Additionally, they will receive personalized counselling from community pharmacists, focused on the specific health and financial benefits of quitting, practical cessation techniques, strategies for overcoming barriers, and relapse prevention. This combined intervention will be provided at baseline and reinforced at a six-month follow-up. Monthly SMS reminders will also be sent, reinforcing key messages on the harmful effects of smoking and benefits of cessation.
  • Other: Routine pharmacy services (no intervention) — Participants in this group will receive only routine pharmacy services based on standard pharmacy practice guidelines applicable in each country. They will not receive any additional graphical health warnings or counselling interventions. Outcomes will be assessed at baseline, 6 months, and 12 months, consistent with the intervention groups.
Study Locations (1 sites)
Global Public Health Research Foundation, Dhaka, Bangladesh
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 and older * Adults (≥18 years) who are current smokers (daily or occasional) and regular visitors to participating pharmacies. * Permanent resident of the study area, * Access to mobile phone * Able to operate smartphone or tablet. Exclusion Criteria: * Without pregnancy and lactation * Without cognitive or psychiatric conditions, * Without severe medical conditions, * Participation in other studies, and inability to consent.
Conditions Breast Adenocarcinoma
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer worldwide, with over 2.2 million new cases diagnosed in 2020. Treatments such as chemotherapy often lead to a reduced exercise capacity, mainly due to cardiovascular and neuromuscular dysfunctions. This decline appears to be primarily caused by increased central fatigue, while peripheral fatigue remains unchanged. This imbalance suggests a hyperactivation of type III-IV afferent nerve fibers, which are involved in the metaboreflex-a mechanism that significantly influences cardiovascular responses during exercise. Two non-invasive methods, post-exercise circulatory occlusion (PECO) and passive leg movement (PLM), will be used to assess this hyperactivity in patients. Additionally, baroreflex function-crucial for regulating blood pressure-will be evaluated using a direct method to determine its sensitivity and reactivity. By comparing patients with healthy controls under submaximal stimuli, this study aims to better understand chemotherapy-induced cardiovascular dysfunctions. Ultimately, the goal is to design personalized exercise programs to restore cardiovascular function and reduce treatment-related side effects.

Design

Study type: Interventional Phases: Allocation: Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Test of neuromuscular fatigue and associated hemodynamic responses — Baseline measurements of neuromuscular function and hemodynamic responses will be performed. Baroreflex sensitivity will be assessed using a neck collar applying positive and negative pressures to stimulate the carotid baroreceptors, thereby modulating baroreflex activity in a dose-dependent manner. Mechanoreflex activation will then be evaluated using the passive leg movement (PLM) technique. After the PLM, participants will perform four fatigue tasks, each followed by 2 minutes of post-exercise circulatory occlusion (PECO). Tasks involve isometric quadriceps contractions at 20% of maximal voluntary contraction (MVC) during 1 min (block 1), 2 min (blocks 2 and 3) and until failure (block4). Neuromuscular function will be assessed through MVC changes and quadriceps twitch responses. Mean arterial pressure (MAP) will be recorded continuously. Metaboreflex activity will be determined by plotting post-PECO changes in peripheral fatigue against the change in MAP during PECO phases.

Primary Outcomes

  • Characterize the metaboreflex in breast cancer patients at the end of chemotherapy treatment (3 weeks after end of chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-02
Completion: 2026-10-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Paul Strauss
Contact Information
Study Contact:
Laura SOMME
0368339523
promotion-rc@icans.eu
Institut de cancérologie Strasbourg Europe
Interventions
  • Other: Test of neuromuscular fatigue and associated hemodynamic responses — Baseline measurements of neuromuscular function and hemodynamic responses will be performed. Baroreflex sensitivity will be assessed using a neck collar applying positive and negative pressures to stimulate the carotid baroreceptors, thereby modulating baroreflex activity in a dose-dependent manner. Mechanoreflex activation will then be evaluated using the passive leg movement (PLM) technique. After the PLM, participants will perform four fatigue tasks, each followed by 2 minutes of post-exercise circulatory occlusion (PECO). Tasks involve isometric quadriceps contractions at 20% of maximal voluntary contraction (MVC) during 1 min (block 1), 2 min (blocks 2 and 3) and until failure (block4). Neuromuscular function will be assessed through MVC changes and quadriceps twitch responses. Mean arterial pressure (MAP) will be recorded continuously. Metaboreflex activity will be determined by plotting post-PECO changes in peripheral fatigue against the change in MAP during PECO phases.
Study Locations (1 sites)
Institut de cancérologie Strasbourg Europe, Strasbourg, 67100 France
Eligibility Criteria
Inclusion Criteria: Patient group : * Stage I to III breast cancer * Having completed (neo)adjuvant chemotherapy treatment less than three weeks ago Control group : \- healthy women (no history of cancer) of similar age, weight, and physical activity level Exclusion Criteria: * History of cancer * Any known chronic pathology * Protected minor or adult * Psychiatric, musculoskeletal or neurological problems * Implantation of a pacemaker * Pregnant woman * Presenting at least one contraindication to the use of transient blood flow occlusion